SCHEMBL6692824

SCHEMBL6692824

NC(=O)c1cccc2c1c1c(O)cccc1n2Cc1ccccc1C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.43
RPS6KB1 P23443 1/20 0.43
AURKB Q96GD4 1/20 0.43
PARP1 P09874 1/20 0.43
KIF11 P52732 5/20 0.43
TDP1 Q9NUW8 1/20 0.43
FABP3 P05413 1/20 0.43
FABP4 P15090 1/20 0.43
RORC P51449 1/20 0.43
CYP3A4 P08684 1/20 0.42
CD38 P28907 1/20 0.42
CYP2C9 P11712 3/20 0.40
EPHX2 P34913 1/20 0.40
PPARG P37231 1/20 0.40
SIRT2 Q8IXJ6 2/20 0.39
SIRT1 Q96EB6 1/20 0.39
MAOB P27338 1/20 0.39
SCD O00767 1/20 0.39
PLA2G2A P14555 1/20 0.38
CCR1 P32246 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6774832 0.88 CD38 (0.44) AURKARPS6KB1AURKBPARP1KIF11
SCHEMBL6782082 0.88 RORC (0.42) AURKARPS6KB1AURKBPARP1KIF11
SCHEMBL6780469 0.87 CYP3A4 (0.41) AURKARPS6KB1AURKBPARP1KIF11
SCHEMBL6694438 0.86 P2RX7 (0.44) KIF11TDP1FABP3FABP4RORC
SCHEMBL6775269 0.86 CYP3A4 (0.40) AURKARPS6KB1AURKBPARP1KIF11
SCHEMBL6776501 0.85 EPHX2 (0.40) AURKARPS6KB1AURKBPARP1KIF11
SCHEMBL6693619 0.84 ALDH1A1 (0.47) AURKARPS6KB1FABP3FABP4PLA2G2A
SCHEMBL6777171 0.83 CYP3A4 (0.38) AURKARPS6KB1AURKBPARP1KIF11
SCHEMBL2585832 0.82 AURKA (0.41) AURKARPS6KB1AURKBPARP1KIF11
SCHEMBL6774411 0.82 AURKA (0.41) AURKARPS6KB1PARP1FABP4CD38

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0952149-B1 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors LILLY CO ELI (US) 2004-06-09 EP disclosed
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed